Search results
AC Immunity Shares Soar on Exclusive License Deal with Takeda
Morningstar· 2 days agoBy Dean Seal Shares of AC Immunity surged after the company signed announced an agreement with Takeda Pharmaceutical for an exclusive option to license ...
Takeda Announces $900 Million Restructure to Improve Profit
Bloomberg· 6 days agoTakeda Pharmaceutical Co. said it will streamline its workforce and lean more heavily on data and...
Japan's Takeda Pharma Outlines $900M Overhaul To Boost Growth, As 2023 Profit Fall Over 50%
Benzinga via Yahoo Finance· 6 days agoOn Thursday, Japan’s drugmaker Takeda Pharmaceutical Company Limited (NYSE:TAK) announced a...
Health Care Climbs as Obesity-Drug Optimism Returns - Health Care Roundup
Morningstar· 6 days agoHealth-care companies rose as optimism about a boom in obesity drugs regained momentum. Novo Nordisk shares ticked up after the maker of obesity injection Wegovy unveiled a research project aimed at adding up to two more obesity treatments to its
Alzheimer’s vaccine licensing deal boosts AC Immune
Market Watch· 2 days agoThe deal gives Japanese drugmaker Takeda the exclusive option to license global rights to the vaccine, known as ACI-24.060, which is designed to delay or...
US FDA extends review of Ascendis Pharma's hormone disorder therapy
Reuters· 19 hours ago, opens new tab therapy to treat adult patients with a hormone disorder by three months, the company...
Improving the safety of iPS cell-derived pancreatic islets by eliminating unwanted cells
Medical Xpress· 2 days agoLtd., and Axcelead Drug Discovery Partners, Inc. The potential of iPS cells to become nearly any cell type in the body also creates concerns about possible risks of...
Groundbreaking Data Collection Platform opens to accelerate research in Central Disorders of...
Loudoun Times-Mirror· 1 day agoSleep Consortium, in partnership with leading sleep-related patient advocacy organizations, the global patient community, and key industry stakeholders, is thrilled to announce the launch of ...
How Neurocrine Is Stacking Up Wins In 2024 — And Outperforming Peers
Investor's Business Daily· 6 days agoIn simple terms, NBI-1065845 works by stimulating neurons in the brain responsible for making...
Bernard Horn's Strategic Moves in Q1 2024: Spotlight on Avnet In
Guru Focus· 5 days agoInsights into Polaris Global Value Fund's Latest Portfolio Adjustments Bernard Horn (Trades, Portfolio), a seasoned investment manager since the early 1980s, l